[1]陈芳芳 综述,李晓军 审校.细胞凋亡在介导非小细胞肺癌耐药调节中的作用[J].医学研究与战创伤救治(原医学研究生学报),2015,17(03):286-289.[doi:10.3969/j.issn.1672-271X.2015.03.020]
点击复制

细胞凋亡在介导非小细胞肺癌耐药调节中的作用()

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第17卷
期数:
2015年03期
页码:
286-289
栏目:
综述
出版日期:
2015-05-20

文章信息/Info

Title:
-
作者:
陈芳芳 综述; 李晓军 审校
210002 江苏南京，南京军区南京总医院中心实验科
Author(s):
-
关键词:
非小细胞肺癌; 凋亡; 耐药
Keywords:
-
分类号:
R734.2
DOI:
10.3969/j.issn.1672-271X.2015.03.020
文献标志码:
A
摘要:
肺癌是我国近年来发病率最高的恶性肿瘤之一，是男性癌症死亡的常见原因，在女性癌症死亡原因中亦仅次于乳腺癌。目前，晚期肺癌的一线治疗是以铂类为基础的联合化疗，较为有效，但对于晚期非小细胞肺癌的治疗及预后则不理想。新的生物标志物及新的分子靶点治疗方法的出现有助于肺癌患者的治疗及预后。尽管如此，耐药仍是肺癌治疗失败、病情进展的主要原因。本文旨在综述凋亡在介导非小细胞肺癌耐药调节中的作用，以更好地了解其基本作用机制，为非小细胞肺癌耐药治疗提供一定的理论依据。
Abstract:
-

参考文献/References:

[1]Ramalingam S，Belani C.Systemic chemotherapy for advanced non-small cell lung cancer：recent advances and future directions[J].Oncologist，2008，13(1)：5-13.
[2]Dempke WC，Suto T，Reck M.Targeted therapies for nonsmall cell lung cancer[J].Lung Cancer，2010，67(3)：257-274.
[3]Belani CP，Langer C.First-line chemotherapy for NSCLC：an overview of relevant trials[J].Lung Cancer，2002，38(4)：13-19.
[4]Srenson S，Glimelius B，Nygren P.A systematic overview of chemotherapy effects in non-small cell lung cancer[J].Acta Oncol，2001，40(2-3)：327-339.
[5]Paez JG，Jnne PA，Lee JC，et al.EGFR mutations in lung cancer：correlation with clinical response to gefitinib therapy[J].Science，2004，304(5676)：1497-1500.
[6]Pao W，Girard N.New driver mutations in non-small-cell lung cancer[J].Lancet Oncol，2011，12(2)：175-180.
[7]Ladanyi M，Pao W.Lung adenocarcinoma：guiding EGFR targeted therapy and beyond[J].Mod Pathol，2008，21(2)：S16-S22.
[8]Pao W，Iafrate AJ，Su Z.Genetically informed lung cancer medicine[J].J Pathol，2011，223(2)：230-240.
[9]Riely GJ，Politi KA，Miller VA，et al.Update on epidermal growth factor receptor mutations in non-small cell lung cancer[J].Clin Cancer Res，2006，12(24)：7232-7241.
[10]Rosell R，Moran T，Queralt C，et al.Screening for epidermal growth factor receptor mutations in lung cancer[J].N Engl J Med，2009，361(10)：958-967.
[11]Rosell R，Carcereny E，Gervais R，et al.Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC)：a multicentre，open-label，randomized phase 3 trial[J].Lancet Oncol，2012，13(3)：239-246.
[12]Soda M，Choi YL，Enomoto M，et al.Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer[J].Nature，2007，448(7153)：561-566.
[13]Shaw AT，Yeap BY，Solomon BJ，et al.Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement：a retrospective analysis[J].Lancet Oncol，2011，12(11)：1004-1012.
[14]Shaw AT，Kim DW，Nakagawa K，et al.Crizotinib versus chemotherapy in advanced ALK-positive lung cancer[J].N Engl J Med，2013，368(25)：2385-2394.
[15]Brose MS，Volpe P，Feldman M，et al.BRAF and RAS mutations in human lung cancer and melanoma[J].Cancer Res，2002，62(23)：6997-7000.
[16]Cappuzzo F，Bemis L，Varella-Garcia M.HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer[J].N Engl J Med，2006，354(24)：2619-2621.
[17]Stephens P，Hunter C，Bignell G，et al.Lung cancer：intragenic ERBB2 kinase mutations in tumours[J].Nature，2004，431(7008)：525-526.
[18]Bean J，Riely GJ，Balak M，et al.Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma[J].Clin Cancer Res，2008，14(22)：7519-7525.
[19]Jones JM，McGonigle NC，McAnespie M，et al.Plasma fibrinogen and serum C-reactive protein are associated with non-small cell lung cancer[J].Lung Cancer，2006，53(1)：97-101.
[20]Zhu JF，Cai L，Zhang XW，et al.High plasma fibrinogen concentration and platelet count unfavorably impact survival in non-small cell lung cancer patients with brain metastases[J].Chin J Cancer，2014，33(2)：96-104.
[21]Sheng L，Luo M，Sun X，et al.Serum fibrinogen is an independent prognostic factor in operable nonsmall cell lung cancer[J].Int J Cancer，2013，133(11)：2720-2725.
[22]Simpson-Haidaris PJ，Rybarczyk B.Tumors and fibrinogen.The role of fibrinogen as an extracellular matrix protein[J].Ann N Y Acad Sci，2001，936：406-425.
[23]Dvorak HF.Tumors：wounds that do not heal.Similarities between tumor stroma generation and wound healing[J].N Engl J Med，1986，315(26)：1650-1659.
[24]Biggerstaff JP，Seth NB，Meyer TV，et al.Fibrin monomer increases platelet adherence to tumor cells in a flowing system：a possible role in metastasis[J].Thromb Res，1998，92(6 Suppl)：53-58.
[25]Palumbo JS，Potter JM，Kaplan LS，et al.Spontaneous hematogenous and lymphatic metastasis，but not primary tumor growth or angiogenesis，is diminished in fibrinogen-deficient mice[J].Cancer Res，2002，62(23)：6966-6972.
[26]Wyllie AH，Kerr JF，Currie AR.Cell death：the significance of apoptosis[J].Int Rev Cytol，1980，68：251-306.
[27]Tait SW，Green DR.Mitochondria and cell death：outer membrane permeabilization and beyond[J].Nat Rev Mol Cell Biol，2010，11(9)：621-632.
[28]Chai J，Wu Q，Shiozaki E，et al.Crystal structure of a procaspase-7 zymogen：mechanisms of activation and substrate binding[J].Cell，2001，107(3)：399-407.
[29]Fuentes-Prior P，Salvesen GS.The protein structures that shape caspase activity，specificity，activation and inhibition[J].Biochem J，2004，384(2)：201-232.
[30]Zhang G.Tumor necrosis factor family ligand-receptor binding[J].Curr Opin Struct Biol，2004，14(2)：154-160.
[31]Pan G，O’Rourke K，Chinnaiyan AM，et al.The receptor for the cytotoxic ligand TRAIL[J].Science，1997，276(5309)：111-113.
[32]Sheridan JP，Marsters SA，Pitti RM，et al.Control of TRAIL induced apoptosis by a family of signaling and decoy receptors[J].Science，1997，277(5327)：818-821.
[33]Letai AG.Diagnosing and exploiting cancer’s addiction to blocks in apoptosis[J].Nat Rev Cancer，2008，8(2)：121-132.
[34]Oltvai ZN，Milliman CL，Korsmeyer SJ.Bcl-2 heterodimerizes in vivo with a conserved homolog，Bax，that accelerates programmed celldeath[J].Cell，1993，74(4)：609-619.
[35]Chittenden T，Harrington EA，O’Connor R，et al.Induction of apoptosis by the Bcl-2 homologue Bak[J].Nature，1995，374(6524)：733-736.
[36]Wei MC，Zong WX，Cheng EH，et al.Proapoptotic BAX and BAK：a requisite gateway to mitochondrial dysfunction and death[J].Science，2001，292(5517)：727-730.
[37]Gao CF，Ren S，Zhang L，et al.Caspase-dependent cytosolic release of cytochrome c and membrane translocation of Bax in p53-induced apoptosis[J].Exp Cell Res，2001，265(1)：145-151.
[38]De Giorgi F，Lartigue L，Bauer MK，et al.The permeability transition pore signals apoptosis by directing Bax translocation and multimerization[J].FASEB J，2002，16(6)：607-609.
[39]Li K，Li Y，Shelton JM，et al.Cytochrome c deficiency causes embryonic lethality and attenuates stress-induced apoptosis[J].Cell，2000，101(4)：389-399.
[40]Verhagen AM，Ekert PG，Pakusch M，et al.Identification of DIABLO，a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins[J].Cell，2000，102(1)：43-53.
[41]Du C，Fang M，Li Y，et al.Smac，a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition[J].Cell，2000，102(1)：33-42.
[42]Hotta K，Matsuo K，Ueoka H，et al.Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced nonsmall-cell lung cancer[J].J Clin Oncol，2004，22(19)：3852-3859.
[43]Wang G，Reed E，Li QQ.Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review)[J].Oncol Rep，2004，12(5)：955-965.
[44]Adams JM，Cory S.The Bcl-2 apoptotic switch in cancer development and therapy[J].Oncogene，2007，26(9)：1324-1337.
[45]Lowe SW，Cepero E，Evan G.Intrinsic tumour suppression[J].Nature，2004，432(7015)：307-315.
[46]Hanahan D，Weinberg RA.The hallmarks of cancer[J].Cell，2000，100(1)：57-70.
[47]Johnstone RW，Ruefli AA，Lowe SW.Apoptosis：a link between cancer genetics and chemotherapy[J].Cell，2002，108(2)：153-164.
[48]Deng J，Carlson N，Takeyama K，et al.BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents[J].Cancer Cell，2007，12(2)：171-185.
[49]Olaussen KA，Dunant A，Fouret P，et al.DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy[J].N Engl J Med，2006，355(10)：983-991.
[50]Majewski N，Nogueira V，Bhaskar P，et al.Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak[J].Mol Cell，2004，16(5)：819-830.
[51]Hanahan D，Weinberg RA.Hallmarks of cancer：the next generation[J].Cell，2011，144(5)：646-674.

相似文献/References:

[1]李爱梅,林夏雯,贾 鹏,等.18F-氟代脱氧葡萄糖诱导MCF-7细胞株的凋亡研究 李爱梅，林夏雯，贾 鹏，郭万华[摘要][J].医学研究与战创伤救治(原医学研究生学报),2011,13(02):112.
　LI Ai-mei,LIN Xia-wen,JIA Peng,et al.Effect of 2-deoxy-2-[18F]fluoro-D-glucose on apoptosis of human MCF-7 cells[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2011,13(03):112.
[2]周诚忠,夏炎春,夏海波.三维适形放射治疗老年非小细胞肺癌60例[J].医学研究与战创伤救治(原医学研究生学报),2009,11(01):20.
　ZHOU Cheng-zhong,XIA Yan-chun,XIA Hai-bao.Analysis of curative effect on 60 elderly non-small cell lung cancer patients treated by three-dimensional conformal radiotherapy[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2009,11(03):20.
[3]洪原城,林平冬,张江灵,等.晚期非小细胞肺癌骨转移的骨相关事件 及生存分析[J].医学研究与战创伤救治(原医学研究生学报),2009,11(02):124.
　HONG Yuan-cheng,LIN Ping-dong,ZHANG Jiang-ling,et al.Skeletal-related events of skeletal metastases in advanced stage non-small cell lung cancer and survival analysis[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2009,11(03):124.
[4]陆春雷,吴国忠,尹天泉,等.细胞粘附在结肠癌细胞系SW480多药耐药表型中的作用[J].医学研究与战创伤救治(原医学研究生学报),2009,11(06):485.
　LU Chun-lei,WU Guo-zhong,YIN Tian-quan,et al.Roles of cell adhesion in multidrug resistance phenotype of colon cancer cell line SW480[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2009,11(03):485.
[5]仇学明,杜云翔,罗红来,等.ZnPPⅨ对胃癌腹膜转移细胞凋亡的影响[J].医学研究与战创伤救治(原医学研究生学报),2009,11(06):495.
　QIU Xue-ming,DU Yun-Xiang,LUO Hong-lai,et al.Effect of ZnPPⅨ on apoptosis of human gastric cancer cell line with peritoneal metastasis[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2009,11(03):495.
[6]柳 刚,张 玲,郭晓军,等.黄芩黄素减轻脱氧胆酸对食管上皮细胞损伤机制的探讨[J].医学研究与战创伤救治(原医学研究生学报),2015,17(02):113.[doi:10.3969/j.issn.1672-271X.2015.02.001]
　LIU Gang,ZHANG Ling,GUO Xiao-jun,et al.Baicalein attenuates deoxycholate-induced injury in human esophageal epithelial cells[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(03):113.[doi:10.3969/j.issn.1672-271X.2015.02.001]
[7]余志阳,潘士勇,刘清珍,等.丙泊酚对帕金森小鼠黑质多巴胺能神经元凋亡的影响[J].医学研究与战创伤救治(原医学研究生学报),2015,17(04):346.[doi:10.3969/j.issn.1672-271X.2015.04.003]
　YU Zhi-yang,PAN Shi-Yong,LIU Qing-zhen,et al.The effect of propofol on apoptosis of dopaminergic neurons in the substantia nigra of mouse model of Parkinson’s disease[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(03):346.[doi:10.3969/j.issn.1672-271X.2015.04.003]
[8]周向毅,丁妍,陈邦元,等.复方康复灵对体部伽玛刀治疗非小细胞肺癌引起的急性放射反应的防护作用[J].医学研究与战创伤救治(原医学研究生学报),2015,17(05):455.[doi:10.3969/j.issn.1672-271X.2015.05.002]
　ZHOU Xiang-yi,DING Yan,CHEN Bang-yuan,et al.Protective effect of compound Kangfuling on body gamma knife in treating acute radiation reaction of non-small cell lung cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(03):455.[doi:10.3969/j.issn.1672-271X.2015.05.002]
[9]丁 虹,唐雯静,庞燕芬,等.马齿苋多糖对宫颈癌细胞恶性生物学行为抑制作用的实验研究[J].医学研究与战创伤救治(原医学研究生学报),2016,18(01):38.[doi:10.3969/j.issn.1672-271X.2016.01.011]
　DING Hong,TANG Wen-jing,PANG Yan-fen,et al.Animal study on the inhibition effect of Portulaca oleracea polysaccharide on malignant behavior of cervical cancer cells[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2016,18(03):38.[doi:10.3969/j.issn.1672-271X.2016.01.011]
[10]吕磊,张洁,殷宇刚,等.川芎嗪减轻大鼠心肌缺血再灌注损伤后心肌细胞凋亡及其机制研究[J].医学研究与战创伤救治(原医学研究生学报),2016,18(04):361.[doi:10.3969/j.issn.1672-271X.2016.04.007]
　LV Lei,ZHANG Jie,YIN Yu-gang,et al.An investigation on the effects of ligustrazine in attenuating apoptosis of myocardial ischemia reperfusion injury in rats and its mechanism[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2016,18(03):361.[doi:10.3969/j.issn.1672-271X.2016.04.007]

备注/Memo

备注/Memo:
国家自然科学基金项目（81171652）
更新日期/Last Update: 2015-05-20